glp-1 and kidney cancer receptor agonists next-generation metabolic hormone therapies in chronic disease GLP-1 drugs may extend life,
Description
To reduce potential gastrointestinal side-effects supplements were increased by 10 g/day every 2 weeks to reach the 30 g/day dose
Evidence that tirzepatide protects against diabetes-related cardiac damages
Stakeholders must act nowbefore regret replaces excitement
Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: Insights from SURPASS clinical program
